Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia

Modern Pathology

Volumn 28, Issue 4, 2015, Pages 596-606

  Jones, Robert T ^a   Abedalthagafi, Malak S ^a   Brahmandam, Mohan ^a   Greenfield, Edward A ^a   Hoang, Mai P ^a   Louis, David N ^a   Hornick, Jason L ^a   Santagata, Sandro ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXONEMAL DYNEIN; B RAF KINASE; DNAH12 PROTEIN; DNAH2 PROTEIN; DNAH7 PROTEIN; ENZYME ANTIBODY; EPITOPE; UNCLASSIFIED DRUG; VE1 ANTIBODY; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ARTICLE; AXONEME; BRONCHUS; CLINICAL ARTICLE; CROSS REACTION; EPENDYMOMA; EPIDIDYMIS; EUKARYOTIC FLAGELLUM; FEMALE; GENE EXPRESSION; GENE MUTATION; HEAVY CHAIN; HUMAN; MALE; MIDDLE AGED; NASOPHARYNX; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RATHKE CLEFT CYST; SEQUENCE HOMOLOGY; SPERMATOZOON TAIL; UTERINE TUBE; BRAIN CYST; BRAIN TUMOR; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; AXONEMAL DYNEINS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM CYSTS; CILIA; CROSS REACTIONS; EPITOPES; HUMANS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84926526320     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.150     Document Type: Article

References (24)

1. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012;123:223-233.
2. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122:11-19.
3. Kato Y, Jin G, Kuan CT, et al. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 2009;390:547-551.
4. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599-601.
5. Preusser M, Capper D, Ilhan-Mutlu A, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123:205-222.
6. Preusser M, Capper D, Hartmann C, et al. testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol 2011;30:217-230.
7. Chan JK, Ip YT, Cheuk W. The utility of immunohistochemistry for providing genetic information on tumors. Int J Surg Pathol 2013;21:455-475.
8. Santagata S, Eberlin LS, Norton I, et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci USA 2014;111:11121-11126.
9. Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014;46:161-165.
10. Voelker JL, Campbell RL, Muller J. Clinical, radiographic, and pathological features of symptomatic Rathke's cleft cysts. J Neurosurg 1991;74:535-544.
11. Shin JL, Asa SL, Woodhouse LJ, et al. Cystic lesions of the pituitary: clinicopathological features distinguishing craniopharyngioma, Rathke's cleft cyst, and arachnoid cyst. J Clin Endocrinol Metab 1999;84: 3972-3982.
12. Buslei R, Nolde M, Hofmann B, et al. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 2005;109: 589-597.
13. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009;4:e7887.
14. Thiru P, Kern DM, McKinley KL, et al. Kinetochore genes are coordinately up-regulated in human tumors as part of a FoxM1-related cell division program. Mol Biol Cell 2014;25:1983-1994.
15. Mordes DA, Lynch K, Campbell S, et al. VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations. Am J Clin Pathol 2014;141:811-815.
16. Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol 1990;215:403-410.
17. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011;6:e17948.
18. Lee EQ, Ruland S, LeBoeuf NR, et al. Successful treatment of a progressive BRAF V600E-mutated anaplastic pleomorphic xanthoastrocytoma with vemurafenib monotherapy. J Clin Oncol advance online publication, 4 August 2014; doi: 10.1200/jco. 2013.51.1766 (e-pub ahead of print).
19. Arisawa M, Makino T, McCann SM, et al. Effect of estrogen on the response of thyroid stimulating hormone to substance P in rats. Endocrinol Jpn 1989;36:899-903.
20. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520.
21. Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009;15:3023-3028.
22. Massi D, Simi L, Sensi E, et al. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. Mod Pathol advance online publication, 24 October 2014; doi: 10.1038/modpathol.2014.137 (e-pub ahead of print).
23. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-444.
24. Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013;45: 285-289.